Abaloparatide 3mg
PTH Receptor Agonist for Bone Density and Anabolic Research
Abaloparatide (Tymlos) is an FDA-approved PTH-related protein analogue that activates the PTH1R receptor to stimulate osteoblast activity, increasing bone mineral density and reducing fracture risk with lower hypercalcemia risk than teriparatide.
PTH Receptor Agonist for Bone Density and Anabolic Research
Abaloparatide selectively biases PTH1R signaling toward bone anabolism with less renal calcium mobilization than PTH or teriparatide. Its FDA approval for postmenopausal osteoporosis establishes its clinical efficacy and safety profile.
As one of the most studied compounds in the longevity research space, Abaloparatide has attracted sustained scientific interest across Bone density research, Osteoporosis studies, PTH receptor biology. Peer-reviewed evidence indicates that fDA-approved as Tymlos for osteoporosis, which has positioned Abaloparatide as a reference standard for researchers exploring bone density research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Abaloparatide Documented Benefits: 3 Documented Mechanisms
Bone Anabolism
Stimulates osteoblast activity and bone formation more selectively than teriparatide in preclinical models.
Reduced Hypercalcemia Risk
Preferential bone vs. renal PTH1R signaling results in less calcium mobilization from bone resorption.
FDA-Approved Mechanism
Clinically validated for osteoporosis treatment, providing a well-characterized safety and efficacy profile.
How Abaloparatide Works: Molecular Mechanism & Pathway
PTHrP(1-34) analogue with selective PTH1R RG conformation bias, driving bone anabolic signaling with reduced renal calcitriol effects.
The 3 primary research pathways identified for Abaloparatide — Bone Anabolism, Reduced Hypercalcemia Risk, FDA-Approved Mechanism — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that increases BMD at spine and hip vs placebo, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Abaloparatide's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Abaloparatide is routinely studied alongside Epitalon and NAD+ in longevity-focused compound panels. Researchers investigating bone density research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that lower hypercalcemia incidence vs teriparatide has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Abaloparatide research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA-approved as Tymlos for osteoporosis
- Increases BMD at spine and hip vs placebo
- Lower hypercalcemia incidence vs teriparatide
Ideal For
- Bone density research
- Osteoporosis studies
- PTH receptor biology
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Abaloparatide. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA-approved as Tymlos for osteoporosis
Increases BMD at spine and hip vs placebo
Lower hypercalcemia incidence vs teriparatide
Third-Party Verified Every Batch
Each vial of Abaloparatide is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
